Renal cancer management is challenging from diagnosis to treatment and follow-up. In
cases of small renal masses and cystic lesions the differential diagnosis of benign or …

Context The incidental detection of localized renal masses has been rising steadily, but a
significant proportion of these tumors are benign or indolent and, in most cases, do not …

Immune checkpoint inhibitor therapy improves survival in patients with metastatic renal cell
carcinoma (RCC) but has not been studied well preoperatively in patients with localized …

For clear cell renal cell carcinoma (ccRCC) risk-dependent diagnostic and therapeutic
algorithms are routinely implemented in clinical practice. Artificial intelligence-based image …

Abstract Purpose of Review We aim to summarize the current state of art about the possible
use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative …

Cell competition, a fitness-sensing process, is essential for tissue homeostasis. Using
cancer metastatic latency models, we show that cell competition results in the displacement …

Importance Clinical trials have shown an overall survival (OS) benefit associated with first-
line immunotherapy (IT) and combination targeted therapy (TT) and IT regimens compared …

Renal cell carcinoma (RCC) represents 2% of all diagnosed malignancies worldwide, with
disease recurrence affecting 20% to 40% of patients. Existing prognostic recurrence models …

Background For patients with nonmetastatic renal cell carcinoma (nmRCC) treated with
nephrectomy, prediction of cancer-specific mortality (CSM) by T stage and substage has not …

Background Renal cell carcinoma is characterized by a late recurrence that occurs 5 years
after surgery; hence, continuous monitoring and follow-up is necessary. Prognosis of late …